Genable Technologies' Series B Round

Genable Technologies raised a round of funding on June 04, 2011.

Genable utilizes well-established, clinically safe and effective AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene …

Articles about Genable Technologies' Series B Round: